Journal of Clinical Medicine (May 2023)

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)

  • Kaisa Lehtomäki,
  • Leena-Maija Soveri,
  • Emerik Osterlund,
  • Annamarja Lamminmäki,
  • Aki Uutela,
  • Eetu Heervä,
  • Päivi Halonen,
  • Hanna Stedt,
  • Sonja Aho,
  • Timo Muhonen,
  • Annika Ålgars,
  • Tapio Salminen,
  • Raija Kallio,
  • Arno Nordin,
  • Laura Aroviita,
  • Paul Nyandoto,
  • Juha Kononen,
  • Bengt Glimelius,
  • Raija Ristamäki,
  • Helena Isoniemi,
  • Pia Osterlund

DOI
https://doi.org/10.3390/jcm12103541
Journal volume & issue
Vol. 12, no. 10
p. 3541

Abstract

Read online

Older adults are underrepresented in metastatic colorectal cancer (mCRC) studies and thus may not receive optimal treatment, especially not metastasectomies. The prospective Finnish real-life RAXO-study included 1086 any organ mCRC patients. We assessed repeated centralized resectability, overall survival (OS), and quality of life (QoL) using 15D and EORTC QLQ-C30/CR29. Older adults (>75 years; n = 181, 17%) had worse ECOG performance status than adults (p < 0.001). The older adults compared with adults were less likely to undergo curative-intent R0/1-resection (19% vs. 32%), but when resection was achieved, OS was not significantly different (HR 1.54 [CI 95% 0.9–2.6]; 5-year OS-rate 58% vs. 67%). ‘Systemic therapy only’ patients had no age-related survival differences. QoL was similar in older adults and adults during curative treatment phase (15D 0.882–0.959/0.872–0.907 [scale 0–1]; GHS 62–94/68–79 [scale 0–100], respectively). Complete curative-intent resection of mCRC leads to excellent survival and QoL even in older adults. Older adults with mCRC should be actively evaluated by a specialized MDT and offered surgical or local ablative treatment whenever possible.

Keywords